The end of AI is healthcare! Wood Sister’s latest report: Disrupting healthcare in the next 5 years, predicting a $12 trillion market for the first time!

Author: Wang Su

Wall Street investment queen Cathie Wood once again demonstrates her investment soul! Recently, her ARK Invest officially released “Big Ideas 2026.” This 111-page report systematically depicts five major innovation platforms changing the world: AI, robotics, multi-omics, blockchain, and energy storage. Cathie Wood, known as “Woodie,” is a dedicated high-growth technology investor focused on “disruptive innovation.” Her fund, ARK Invest, is committed to investing in technological platforms that may change the world.

ARK Invest’s annual “Big Ideas” series reports not only embody its core investment philosophy but also serve as a must-read annual trend indicator for global tech investors. The report states: We are entering an era of “big acceleration” driven by AI, robotics, energy storage, blockchain technology, and multi-omics sequencing, which will trigger a global productivity revolution and unprecedented economic growth. Let’s look at some perspectives ARK shares in the medical field. Woodie firmly believes that the entire healthcare sector is on the verge of being ignited by “AI + multi-omics.” Over the next five years, we will witness a massive transformation in healthcare: data explosion: genome sequencing costs drop tenfold, data volume increases tenfold.

Diagnosis upgrade: earlier, more precise, AI-driven diagnostic tools grow five times; R&D efficiency: drug development costs reduce fourfold, commercialization speed increases 1.6 times; paradigm shift: from “treating diseases” to “achieving cures,” leading to a qualitative leap in human lifespan;

This wave is far more than a medical revolution; it will profoundly reshape the global economic landscape, capital allocation logic, and even human lifestyles.

When biology meets “Moore’s Law”

Woodie emphasizes, “You must focus on sequencing technology; it’s the starting point.” Biological data is almost the highest barrier in all industries, and breakthroughs in sequencing technology make it possible for researchers to obtain and analyze large amounts of biological data at lower costs. Multi-omics refers to a technical system that analyzes multiple biological data layers simultaneously, including five major technologies: DNA, epigenomics, RNA, proteomics, and metabolomics.

Today, the cost of multi-omics sequencing is decreasing exponentially, showing a “biological version of Moore’s Law” trend. ARK predicts that by 2030, the cost to sequence the entire human genome could drop about tenfold, down to $10 (currently around $100).

This will lead to an explosive growth in molecular detection data, with data volume increasing tenfold by 2030.

It’s important to note that the current rapid growth in data volume has already surpassed the amount needed for training large language models by general AI companies like OpenAI, Google, Anthropic, and xAI (150 trillion tokens).

More importantly, the reduction in sequencing costs not only causes data explosion but also creates a powerful technological flywheel: more biological data — better models — better tools — better diagnostics and drugs.

ARK predicts that by 2030, the entire healthcare landscape will look like this: whole-genome sequencing costs decrease tenfold, sequencing demand for diagnostics increases tenfold; molecular detection data volume increases tenfold. AI-driven diagnostic technology grows five times; drug development costs are reduced fourfold, and commercialization speed increases 1.6 times. Therefore, the biggest investment opportunities will be in platform companies that integrate data, algorithms, and therapies, as well as in companies making breakthroughs in gene editing, cell therapy, AI drug discovery, and other key technologies.

It’s not just life sciences; over time, the development of multi-omics technology will also bring advances in agriculture, materials science, and even computing.

AI, revolutionizing drug discovery

It is well known that drug development follows a “double ten law,” meaning it costs one billion dollars and takes about ten years for a drug to reach patients. But in reality, the costs are much higher: developing a drug requires $2.4 billion and 13 years. Moreover, the long R&D process consumes patent periods and negatively impacts post-market revenue. ARK predicts that AI-driven drug development could shorten the time to market by about 40%, from 13 years to 8 years, and reduce the total cost by about four times, from $2.4 billion to $700 million, a 70% reduction.

Additionally, the failure rate in drug R&D will further decrease. Phase I failure rate drops from 43% to 25%, and combined Phase II and III failure rates fall from 65% to 35%. More importantly, the report points out that the value growth of AI-based drug discovery is compound: not only cost reduction but also faster market entry and extended patent protection for revenue.

Currently, AI has shortened R&D cycles by 2-3 years, increasing patent value by 30%-50%; in the future, if cycles are shortened to 4-5 years, the increase in patent value could reach 70%-80%. This efficiency advantage directly translates into cash flow, with AI drugs potentially generating around $4 billion in cumulative cash flow, four times that of traditional drugs.

Furthermore, AI drugs can generate approximately $3 billion in cash flow within the time window before traditional drugs break even, greatly improving ROI. Additionally, ARK believes that diseases are shifting from treatment to cure, placing high importance on the value brought by gene editing and other technologies.

Although a single cure might cost over $1 million, it can save the costs of lifelong medication, making its value 20 times that of traditional chronic disease drugs.

Longevity technology, a $120 trillion opportunity

In the “Big Ideas 2026” report, ARK for the first time highlights longevity technology as a new independent segment. This marks an important evolution in its research perspective: as multi-omics, AI, and gene editing tools mature, scientists are shifting from merely treating diseases to actively intervening in the aging process itself. Today, the average life expectancy has increased dramatically from 46.5 years in 1950 to 73 years in 2023.

The medical advances of the past century mainly focused on fighting specific diseases like cancer, thereby extending average lifespan but not addressing the fundamental biological processes of aging. Therefore, the new goal of longevity technology is to target the biological roots of aging: directly intervene in cellular and molecular changes that cause functional decline, such as DNA damage, mitochondrial dysfunction, and epigenetic drift. By integrating multi-dimensional data and using AI to establish epigenetic clocks and cell reprogramming, these technologies are more effectively monitoring and reversing aging processes.

This is not just about living longer, but about living better.

Building on this, the report attempts to quantify the economic potential of longevity technology, presenting a highly impactful view.

Calculating at $100k per healthy life year, just the potential increase in lifespan in the U.S. represents a market opportunity of $1200 trillion (1.2 quadrillion dollars)!

In comparison, the current global biotech market accounts for only 0.1% of this potential. Worldwide, startups and investments in longevity tech are surging, forming an active ecosystem. A number of longevity tech companies have emerged, attracting Silicon Valley billionaires’ attention, such as Altos Labs, Retro Biosciences, Juvenescence, and New Limit. In short, the report depicts a future driven by technology and data, where efficiency revolutions and paradigm shifts in healthcare are nurturing the next generation of giant investment opportunities.